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Background: The pathogenesis between cerebral vascular disease (CVD) and the endothelial dysfunction (ETD)
remains elusive in diabetes. Therefore, we investigated the expression of partial vasoactivators which be closely
relative to ETD in CVD susceptible brain regions in the diabetic rat. The aim was to search some possible
pathogenesis.
Methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin and a high lipid/sugar diet.
The expression of vasoactivators ET-1, CGRP, VCAM-1, ICAM-1 and P-selectin were assessed by
immunohistochemical staining and measurement of optic density of positive cells in the frontal and temporal lobe,
basal ganglia and thalamus at 4 weeks after establishment of the diabetic model.
Results: The expression of ET-1, VCAM-1, ICAM-1 and P-selectin significantly increased and CGRP significantly
decreased in the diabetic group, and the expression of these vasoactivators was significantly different among the
frontal, temporal lobe, basal ganglia and thalamus, and among the emotion, splanchno-motor and neuroendocrine
center in the diabetic group.
Conclusions: Diabetes alters the expression of partial vasoactivators in cerebral vascular disease susceptible regions
of the diabetic rat. Therefore, we suggested that CVD complications in diabetes are partly caused by ETD via an
imbalance expression of endothelial vasoactivators, which might be associated with dysfunction of emotion,
autonomic nerve and endocrine center. However, further studies are warranted.
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The diabetes epidemic continues to grow. In the year 2000,
there was an estimated 171 million patients worldwide with
a diabetes diagnosis. This number is projected to rise to
366 million by 2030, with 90% having a diagnosis of type 2
diabetes (T2DM) [1]. T2DM is more common in people
older than 45 who are overweight. It is a major risk factor
for cerebral vascular diseases (CVD) and is associated with
accelerated atherosclerosis and a high rate of arterial
thrombotic complications. Patients with T2DM have a
higher incidence of stroke and a poorer prognosis after
stroke. T2DM is associated with both micro- and macro-
vascular complications that can lead to significantly elevated* Correspondence: xurenshi@yahoo.com
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reproduction in any medium, provided the orincidence of CVD and is frequently associated with athero-
sclerotic vascular disease involving CVD. A number of
studies support the concept that endothelial dysfunction
(ETD) contributes to the pathogenesis and progression of
the vascular complications in diabetes [2-6].
ETD plays a key role in the initiation of cellular events
evolving into the development of vascular complications in
diabetes, and it is regarded as an important factor in the
pathogenesis of vascular disease in obesity-related T2DM
[3]. The abnormal production of endothelium-associated
factors/vasoactivators including vascular oxidative stress [4],
inflammatory reaction, nitric oxide (NO), prostanoids (pros-
tacyclin), endothelin-1 (ET-1), angiotensin II (ANG-II),
tissue-type plasminogen activator (t-PA), plasminogen acti-
vator inhibitor-1 (PAI-1), von Willebrand factor (vWF), ad-
hesion molecules (Vascular cell adhesion molecule, VCAM;This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ecule, ICAM), and cytokines leads to ETD [3]. This results
in elevating vascular tone, which contributes to microvascu-
lar and macrovascular damages and apoptosis of micro-
vascular cells, ultimately leading to diabetes-related vascular
complications [3].
In a variety of pathological circumstances, the balance of
these regulatory mediators is altered, resulting in the onset
and progression of vascular ETD [5]. Vascular ETD in-
creases interactions with leukocytes, smooth muscle growth,
vasoconstriction, impaired coagulation, vascular inflamma-
tion, thrombosis, and atherosclerosis, which are the basis of
most late diabetic complications such as retinopathy, ne-
phropathy, vasculopathy and neuropathy [6].
The pathogenesis of diabetic vasculopathy in T2DM is
very complicated due to the many independent factors in-
volved. The relationship of diabetic CVD complications
and the ETD-associated factors mentioned above is not
completely understood, despite extensive research [2-6].
And there are fewer reports on ET-1, calcitonin gene re-
lated peptide (CGRP), VCAM-1, ICAM-1 and P-selectin
expression in the CVD susceptible brain regions of diabetic
rats. Moreover, we observed that these vasoactivators ex-
tensively expressed in the rat brain in our previous experi-
mental results (The data no published). Therefore, in this
study, we will further investigate the alterations of individ-
ual endothelial function-associated factors like ET-1, CGRP,
VCAM, ICAM-1 and P-selectin in the susceptible brain re-
gions of CVD such as frontal and temporal cerebral cortex,
basal ganglia and thalamus (including the hypothalamus) in
a rat model of T2DM. The aim is to search the applicable
optimal candidate methods for specific therapies targeting
these factors using moderators of the endothelial function
system, which might assist to reverse vascular ETD and
thus reduce the morbidity and mortality of the related
CVD in diabetes. The results from our studies indicate that
ET-1, VCAM-1, ICAM-1, P-selectin and CGRP expression
in the partial frontal and temporal cortex, basal ganglia, nu-
clei of hypothalamus and the inferior part of the thalamus
is significantly altered in the diabetic rat model. It might be
of importance to retrieve the imbalance of ET-1, VCAM-1,
ICAM-1, P-selectin and CGRP expression in the prevention
of complications related to diabetic CVD.
Methods
Diabetic rat model
Sprague–Dawley rats were made diabetes by a single intra-
peritoneal injection of 0.1 mmol/L STZ buffer solution
(STZ, 30 mg/kg body weight, Sigma Co. Ltd., USA) and a
high lipid/sugar diet (common animal feed 66.5%, sugar
20%, lard 10%, cholesterol 2.5%, sodium cholate 1%) [7,8].
Weight- and age-matched control rats were injected with
an equal volume of citric acid buffer solution and fed a rou-
tine diet. The blood of rat tail vein was taken for measureof blood glucose and insulin levels at baseline and the end-
point after 4 weeks of streptozotocin intraperitoneal injec-
tion. Only STZ-injected rats with above 15 mM of a
fasting blood glucose level at endpoint were included in
this study as the diabetic rats. Body weight, insulin levels
and insulin sensitivity were monitored. Food and fluid in-
take as well as urine production were evaluated at baseline
and after 4 weeks. Four weeks after the induction of dia-
betes, according to Longa’s standard of 5 levels of 4 scores,
rats that received scores of 0 were allowed into the follow-
ing experiments. The diabetic rats were sacrificed, and
brain tissues were processed for experimental analysis. All
rats in our experiment were male, the average age in the
endpoint of experiment was 14.2 month. Each group
consisted of 10 rats. All animal studies were conducted in
accordance with the Guide for the Care and Use of Labora-
tory Animals of China. All experiments involving rats were
reviewed and approved by the ethics committee for animal
care and use of the First Affiliated Hospital of Nanchang
University, China (Permit nr: 8/21.01.2009).
Blood glucose, insulin levels and insulin sensitivity index
measurement
The rat vein blood for blood glucose and insulin level mea-
surements was drawn after 12 hours of fasting. Blood glu-
cose levels were measured by Roche glucometer (Roche
Group, Switzerland). Insulin levels were measured by
radioimmunoassay with a kit (Shandong Weifang 3 V Bio-
engineering Group. Ltd., China). Insulin sensitivity index
(ISI) was determined by the following formula: ISI = 1/
(Blood glucose level + Insulin level).
Immunohistochemical staining
Control and diabetic rats were anesthetised and perfused
with 200 ml 0.9% cold saline and 400 ml 4% PFA in 1xPBS
(pH 7.5) at room temperature. Rat brains were excised and
placed in 4% PFA buffer overnight, followed by incubation
in 20% sucrose in 1×PBS (pH 7.5) for 3 days. The brains
were then embedded. The tissue was coronally sectioned
using successive 30 μm cuts on a cryostat from the occipi-
tal to frontal lobe and collected on slides. For immunohis-
tochemical staining, sections were permeated with 0.2%
Triton X-100 and blocked with 10% goat serum in 1xPBS
after being rehydrated in 1xPBS (pH 7.4). Sections were
then incubated at 4°C overnight with the following anti-
bodies: ET-1, CGRP (Sigma Co. Ltd.), VCAM-1, ICAM-1
and P-selectin (Sigma Co. Ltd.). All antibodies were diluted
1:50. Sections were then mildly washed 6 times with 0.2%
Triton X-100 in 1×PBS for 5 minutes. Incubated with sec-
ondary antibody diluted 1:200 for 2 hours at room
temperature(RT), extensively washed 3 times with 1xPBS
for 5 minutes, and incubated with ABC compounds diluted
1:100 for 2 hours at RT, extensively washed 3 times with
1×PBS for 5 minutes. Stained with 0.03% DAB and 0.006%
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nutes at RT. Wash with ddH2O, counterstained with
hematoxylin for 2 minutes, routinely dehydrated with alco-
hol, mounted with resin and examined under a light micro-
scope with a spot digital camera. All immunohistochemical
staining sections were observed, and pictures were taken.
Image collection and analysis
All images were collected with a light microscope with a
digital camera and analysed with image analysis soft-
ware. For semi-quantification of positive cells, the im-
ages were displayed on a computer monitor at 20×
magnifications. Optic density (OD) of the positive cells
was measured with Image-Pro Plus 6.0 software (Media
Cybernetics Co. Ltd., USA). Fifty positive cells from
each distinct brain region were randomly chosen, 10
sections per animal with 10 rats per group. The OD of
total positive cells for each chosen brain region was cal-
culated. The average OD of each region was used for
comparing the differences between the control and dia-
betic group. The average OD difference (Average OD
difference = average diabetic OD - average control OD)
was used to compare and analyze the rank order (from
more to fewer) of the expression quantity change of
ET-1, CGRP, VCAM-1, ICAM-1 and P-selectin in dis-
tinct brain regions.
Statistical analysis
Statistical analysis of the data was performed using a
Student’s t-tests. All data are presented as means ± SD.
p < 0.05 was considered to be statistically significant.
Results
Baseline and endpoint characteristics in the control and
diabetic rat
Table 1 presents baseline and endpoint characteristics of
both nondiabetic (Control group) and diabetic rats (Dia-
betic group). On the comparison of baseline and endpoint
characteristics between control and diabetic rats, the dia-
betic rats showed an approximately five-fold increase in
blood glucose levels, decreased weight gain and decreasedTable 1 Comparison of baseline and endpoint
characteristics in the control and diabetic rats
Characteristics Nondiabetic rats Diabetic rats
Baseline Endpoint Baseline Endpoint
Blood glucose
(mmol/L)
4.46 ± 0.39 4.70 ± 0.59 4.55 ± 0.23 20.9 ± 0.83*
Weight (g) 440.53 ± 10.33 498.55 ± 10.5 442 ± 9.66 390 ± 10.23*
Blood insulin
(mU/L)
3.3 ± 0.24 3.25 ± 0.28 4.23 ± 0.37 77.16 ± 7.78*
Insulin
sensitivity index
0.12 ± 0.05 0.13 ± 0.03 0.14 ± 0.02 0.02 ± 0.002*
*P < 0.05, Compared with baseline.insulin sensitivity, also showed a increased insulin level,
increased food and fluid intake and increased urine pro-
duction at endpoint. The baseline and endpoint character-
istics besides the physiological weight gain didn’t show
any statistical difference in nondiabetic rats (Table 1).Expression of ET-1 significantly increased in partial cerebral
cortex, basal ganglia and thalamus of diabetic rats
In the observed CVD susceptible brain regions, the ET-1
expression significantly increased in partial frontal and
temporal cortex, basal ganglia, hypothalamus and the infer-
ior part of thalamus (Figure 1A-H) in diabetic rats. The
rank order (from more to fewer) of ET-1 expression quan-
tity change in the diabetic rats showed that the partial tem-
poral cortex and basal ganglia exhibited greater change
than the frontal cortex. The frontal cortex exhibited greater
change than the hypothalamus, which exhibited greater
change than the inferior part of the thalamus (i.e., Partial
temporal cortex and basal ganglia > frontal cortex > hypo-
thalamus > inferior part of thalamus.) (Figure 1G, H). The
regions with significantly altered ET-1 roughly included
the amygdaloid nucleus (Amyg), posterior interposed nu-
cleus (Pir), endopiriform nucleus (En), interstitial nucleus
of posterior limb of anterior commissure (IPAC), nucleus
of stria terminalis (BsTIA) and lateral globus pallidus
(LGP) in the temporal cortex and basal ganglia; the
retrosplenial agranular cortex (RSA), retrosplenial granu-
lar cortex (RSG), primary motor cortex (M1) and supple-
mentary motor cortex (M2) in the frontal cortex; the
dorsomedial nucleus of hypothalamus (DM), hypothal-
amic nucleus (HyT), supraoptic nucleus (SO), subincertal
nucleus (SubI), zona incerta (ZI), xiphoid thalamic nucleus
(Xi) and lateral hypothalamic area (LH) in the hypothal-
amus; and the paraventricular thalamic nucleus (PV),
habenular nucleus (Hb) and mediodorsal thalamic nucleus
(MD) in the inferior part of the thalamus.Expression of CGRP significantly decreased in the partial
cerebral cortex and thalamus of diabetic rats
CGRP expression significantly decreased in the partial
temporal cortex, hypothalamus and inferior part of
the thalamus in diabetic rats (Figure 2A-H). The rank
order of CGRP expression quantity change was partial
temporal cortex > hypothalamus > inferior part of thalamus
(Figure 2G, H), CGRP expression in the frontal cortex were
not significant difference in the comparison of control and
diabetic rats (No data shown). These significantly altered
regions roughly consisted of Pir, En, Amyg, entorhinal cor-
tex (Ent), perirhinal cortex (PRh) and ectorhinal cortex
(Ect) in the temporal cortex; DM, HyT, SO, SubI, ZI, Xi
and LH in the hypothalamus; and Hb, PV and MD in the
inferior part of the thalamus.
Figure 1 ET-1 expression in distinct brain regions was compared by measuring the OD (Optic density) of positive cells in brains of
control and diabetic rats with immunohistochemical staining. (A). The representative image of ET-1 expression in the cerebral cortex of
control rats. (B). The representative image of ET-1 expression in the cerebral cortex of diabetic rats. (C). The OD comparison of ET-1 expression
positive cells in cerebral cortex between control and diabetic rats. ET-1 expression in the cerebral cortex of diabetic rats significantly increases
compared with control rats (*P < 0.05). (D). The representative image of ET-1 expression in the thalamus of control rats. (E). The representative
image of ET-1 expression in the thalamus of diabetic rats. (F).The OD comparison of ET-1 expression positive cells in thalamus between control
and diabetes rats. ET-1 expression in the thalamus of diabetes rats significantly increases compared with control rats (*P < 0.05). (G).Schematic
representation indicates brain regions where ET-1 expression is significantly altered in diabetic rats and the rank order (from more to fewer) of
expression quantity change in distinct regions of the integral brain. (H).The comparison of ET-1 expression quantity change in distinct brain
regions. ET-1 expression quantity change is significantly different in distinct brain regions of diabetic rats (*P < 0.05). The black arrow indicates the
positive cell. The marked number in distinct regions of the rat brain atlas reflects the rank order (from more to fewer) of expression quantity
change in distinct regions of integral brain in all figures. Bar = 50 μm. Abbr. Basal ganglia, BG; Frontal cortex, FC; Hippocampus, HI; Hypothalamus,
HT; Inferior part of thalamus, IPT; Partial frontal cortex, PFC; Partial temporal cortex, PTC; Temporal cortex, TC; Thalamus, TH.
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partial cerebral cortex, hypothalamus and hippocampus
of diabetic rats
VCAM-1 expression significantly increased in partial frontal
cortex, temporal cortex, hypothalamus and hippocampus in
diabetic rats (Figure 3A-K). The rank order of VCAM-1 ex-
pression quantity change was partial frontal cortex > tem-
poral cortex > hypothalamus > hippocampus (Figure 3J, K).
These significantly altered regions were roughly constructed
by M1, M2 and RSA in the frontal cortex; Pir, En, Amyg in
the temporal cortex; DM, SubI in the hypothalamus; and
CA2, CA3 in the hippocampus.Expression of ICAM-1 significantly increased in the partial
cerebral cortex of diabetic rats
ICAM-1 expression significantly increased in the partial
frontal and temporal cortex in diabetic rats (Figure 4A-E).The rank order of ICAM-1 expression quantity change was
partial frontal cortex > temporal cortex (Figure 4D, E). These
significantly altered regions were roughly constructed by
M1, M2 and RSA in the frontal cortex and by the second
somatosensory cortex (S2), Ect, PRh, Ent, Pir, En and Amyg
in the temporal cortex.Expression of P-selectin significantly increased in the
partial cerebral cortex, basal ganglia, almost integral
hippocampus and thalamus of diabetic rats
P-selectin expression significantly increased in the partial
frontal and temporal cerebral cortex, almost integral hippo-
campus and thalamus in diabetic rats (Figure 5A-K). The
rank order of ICAM-1 expression quantity change was
hippocampus > thalamus > temporal cortex and basal gan-
glia > frontal cortex (Figure 5J, K). These significantly altered
regions roughly included the dentate gyrus (DG), CA1, CA2
Figure 2 CGRP expression in distinct brain regions were compared by measuring the OD of positive cells in brains of control and
diabetic rats with immunohistochemical staining. (A). The representative image of CGRP expression in the cerebral cortex of control rats. (B).
The representative image of CGRP expression in the cerebral cortex of diabetic rats. (C). The OD comparison of CGRP expression positive cells in
cerebral cortex between control and diabetic rats. CGRP expression in the cerebral cortex of diabetic rats significantly decreases compared with
control rats (*P < 0.05). (D). The representative image of CGRP expression in the thalamus of control rats. (E). The representative image of CGRP
expression in the thalamus of diabetic rats. (F). The OD comparison of CGRP expression positive cells in thalamus between control and diabetic
rats. CGRP expression in the thalamus of diabetic rats significantly decreased compared with control rats (*P < 0.05). (G). Schematic representation
indicates brain regions where CGRP expression is significantly altered in diabetic rats and the rank order (from more to fewer) of expression
quantity change in distinct regions of the integral brain. (H). The comparison of CGRP expression quantity change in distinct brain regions.
CGRP expression quantity change is significantly different in distinct brain regions of diabetic rats (*P < 0.05). Bar = 100 μm.
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Amyg, Pir, En, IPAC, BsTIA and LGP in the temporal cortex
and basal ganglia; and M1, M2, RSA and RSG in the frontal
cortex.
Discussion
In this study, rats consistent with the characteristics of a
diabetic rat model and scores of 0 based on Longa’s
standard were selected as the diabetic rat model of
stroke prophase. ET-1, CGRP, VCAM-1, ICAM-1 and
P-selectin expression was semi-quantitatively analyzed
by immunohistochemical staining and the measurement
of OD of immunohistochemical positive cells. The posi-
tions of various brain regions were located using an
atlas (The Rat Brain in Stereotaxic Coordinates, Sixth
Edition: Hard Cover Edition). The expression changes
of endothelium-associated factors/vasoactivators, in-
cluding ET-1, CGRP, VCAM-1, ICAM-1 and P-selectin,
were compared and analyzed in CVD-susceptible brainregions such as the frontal and temporal cortex, basal
ganglia and thalamus.
The results of this study provide several lines of evi-
dence implicating CVD in T2DM. First, these data dem-
onstrate that the expression of ET-1, VCAM-1, ICAM-1,
P-selectin and CGRP is significantly altered (increased or
decreased) in multiple brain regions, including the partial
frontal and temporal cerebral cortex, basal ganglia, hippo-
campus and thalamus, in diabetic rats at 4 weeks post-
induction of diabetes. These described brain regions are
the susceptible brain regions of CVD; therefore, the data
indicate that cerebral vascular complications in T2DM are
associated with alterations of these endothelial function-
associated factors. Second, our results contribute to a
growing body of evidence indicating that the ETD contrib-
utes to CVD in T2DM by an imbalance of ET-1, CGRP,
VCAM-1, ICAM-1 and P-selectin expression, because the
imbalance of these endothelial function-associated factors
contributes to ETD responses. The data also support that
Figure 3 VCAM-1 expression in distinct brain regions were compared by measuring the OD of positive cells in brains of control and
diabetic rat with immunohistochemical staining. (A). The representative image of VCAM-1 expression in the cerebral cortex of control rats.
(B). The representative image of VCAM-1 expression in the cerebral cortex of diabetic rats. (C). The OD comparison of VCAM-1 expression positive
cell in cerebral cortex between control and diabetic rats. VCAM-1 expression in the cerebral cortex of diabetic rats significantly increases
compared with control rats (*P < 0.05). (D). The representative image of VCAM-1 expression in the thalamus of control rats. (E). The representative
image of VCAM-1 expression in the thalamus of diabetic rats. (F). The OD comparison of VCAM-1 expression positive cells in thalamus between
control and diabetic rats. VCAM-1 expression in the thalamus of diabetic rats significantly increases compared with control rats (*P < 0.05). (G).
The representative image of VCAM-1 expression in the hippocampus of control rats. (H). The representative image of VCAM-1 expression in the
hippocampus of diabetic rats. (I). The OD comparison of VCAM-1 expression positive cells in hippocampus between control and diabetic rats.
VCAM-1 expression in the hippocampus of diabetic rats significantly increases compared with control rats (*P < 0.05). (J). Schematic
representation indicates brain regions where VCAM-1 expression is significantly altered in diabetic rats and the rank order (from more to fewer) of
expression quantity change in distinct regions of integral brain. (K). The OD comparison of positive cells between control and diabetic rats;
VCAM-1 expression significantly increases in the hippocampus of diabetic rats (*P < 0.05). Bar = 100 μm.
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selectin expression play a role in CVD complications in
T2DM via ETD. Third, the significant expression alter-
ations of ET-1, CGRP, VCAM-1, ICAM-1 and P-selectin
occurs in emotion center (partial temporal cortex and
hippocampus of the limbic lobe), cerebral splanchno-
motor center (partial M1, M2 and RSA in the frontal cor-
tex), and neuroendocrine center (partial nuclei in the
hypothalamus and inferior thalamus), which might dir-
ectly or indirectly mediate expression of these factors inT2DM via the central nervous system. Furthermore, the
abnormal brain vascular constriction and vasodilation
caused by an imbalance of ET-1 and CGRP expression
and the increase in brain vascular permeability induced by
abnormal expression of VCAM-1, ICAM-1 and P-selectin
participate in CVD complications in T2DM by ETD,
which provides new evidence for preventing the related
CVD in diabetes. In addition, there is a significant differ-
ence in the expression of studied vasoactivators in the dif-
ferent brain regions of diabetic rats. This may indicate that
Figure 4 ICAM-1 expression in distinct brain regions were compared by measuring the OD of positive cells in the brains of control and
diabetic rat with immunohistochemical staining. (A). The representative image of ICAM-1 expression in the cerebral cortex of control rats. (B).
The representative image of ICAM-1 expression in the cerebral cortex of diabetic rats. (C). The OD comparison of ICAM-1 expression positive cell
in cerebral cortex between control and diabetes rats. ICAM-1 expression in the cerebral cortex of diabetic rats significantly increases compared
with control rats (*P < 0.05). (D). Schematic representation indicates brain regions where ICAM-1 expression is significantly altered in diabetic rats
and the rank order (from more to fewer) of expression quantity change in distinct regions of the integral brain. (E). The comparison of ICAM-1
expression quantity change in distinct brain regions. ICAM-1 expression quantity change is significantly different in distinct brain regions of
diabetic rats (*P < 0.05). Bar = 100 μm.
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ant role in the modulation and function of the individual
vasoactivator.
Although the pathogenesis of ETD is not completely
clear, it is generally accepted that ETD is caused by an
imbalance between endothelium-derived vasodilator and
vasoconstrictor substances. ET-1 is a potent vasocon-
strictor produced by endothelial cells (EC). The production
and the plasma levels of ET-1 are elevated in patients with
diabetes, and a positive correlation between plasma ET-1
levels and diabetic microangiopathy has been reported.
Thus, it is possible that ET-1 plays a potential role in ETD
by an imbalance between endothelium-derived vasodilator
and vasoconstrictor substances on the pathophysiology of
vascular complications in diabetes [9].
In this study, we studied ET-1 expression in the suscep-
tible brain regions of CVD in a rat model of T2MD and
compared it with the expression in controls. It was found
that ET-1 expression was significantly elevated in the par-
tial frontal and temporal cortex, basal ganglia, hypothal-
amus and inferior part of the thalamus in diabetic rats.
These brain regions are susceptible to atherosclerosis and
CVD (See Figure 1A-H). The exact mechanism by which
ET-1 causes CVD and/or ETD in T2DM is not completely
known yet; however, there are deleterious effects on the
studied brain regions causing EC damage and increased
local vasoconstriction of these brain regions, ultimately
leading to brain vascular damage such as atherosclerosisand chronic brain ETD. In addition to its direct vasocon-
strictor effects, enhanced levels of ET-1 may contribute to
ETD through the production of a series of vascular active
factors, including ROS (reactive oxygen species), NO and
inflammatory factors [10-12].
CGRP is an important moderator of ET-1 vasocon-
striction. The decrease in CGRP expression results in an
imbalance in the CGRP/ET-1 ratio, which induces ab-
normal vasoconstriction to contribute to direct and/or
indirect local ETD and vascular damage [13,14]. In our
results, diabetes induced a significantly decreased im-
munoreactivity of CGRP in the partial temporal cortex,
hypothalamus and inferior part of the thalamus (See
Figure 2A-H), which indicates that diabetes contributes
to decreases CGRP expression within the CVD suscep-
tible regions. The markedly decreased CGRP expression
in the distinct brain regions of rats subjected to diabetes
results in an imbalance of CGRP and ET-1 content.
Therefore, we suggests that an imbalance of CGRP and
ET-1 content in CVD-susceptible regions might take
part in the development of CVD in T2DM via ETD.
VCAM-1 is one of the major endothelial receptors that
mediate leukocyte adhesion to the vascular endothelium.
Recent data have strongly suggested that VCAM-1 may
play an important role in the pathogenesis of atheroscler-
osis because VCAM-1 function in leukocyte adhesion and
transmigration is crucial and its expression is induced early
in nascent atheroma plaques [15]. In addition, VCAM-1
Figure 5 P-selectin expression in distinct brain regions were compared by measuring the OD of positive cells in brains of control and
diabetic rat with immunohistochemical staining. (A). The representative image of P-selectin expression in the cerebral cortex of control rats.
(B). The representative image of P-selectin expression in the cerebral cortex of diabetic rats. (C). The OD comparison of P-selectin expression
positive cell in cerebral cortex between control and diabetes rats. P-selectin expression in the cerebral cortex of diabetic rats significantly
increases compared with control rats (*P < 0.05). (D). The representative image of P-selectin expression in the thalamus of control rats. (E). The
representative image of P-selectin expression in the thalamus of diabetic rats. (F). The OD comparison of P-selectin expression positive cells in
thalamus between control and diabetic rats. P-selectin expression in the thalamus of diabetic rats significantly increases compared with control
rats (*P < 0.05). (G). The representative image of P-selectin expression in the hippocampus of control rats. (H). The representative image of P-
selectin expression in the hippocampus of diabetic rats. (I). The OD comparison of P-selectin expression positive cells in hippocampus between
control and diabetic rats. P-selectin expression in the hippocampus of diabetic rats significantly increases compared with control rats (*P < 0.05).
(J). Schematic representation indicates brain regions where P-selectin expression is significantly altered in diabetic rats and the rank order (from
more to fewer) of expression quantity change in distinct regions of the integral brain. (K). The comparison of P-selectin expression quantity
change in distinct brain regions. P-selectin expression quantity change is significantly different in distinct brain regions of diabetic rats
(*P < 0.05). Bar = 100 μm.
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ing TNF-α and IL-1β, and is mediated, at least in part, by
NF-kb [16]. VCAM-1 expression is also induced under
vascular stress conditions such as insulin resistance and
chronic hyperglycaemia. Under these conditions, an in-
crease in VCAM-1 expression activity was also observed
[17,18]. In addition to binding leukocytes, VCAM-1 en-
gagement contributes to leukocyte transendothelial migra-
tion (TEM) by stimulating gap formation between cells in
the endothelial monolayer, which could facilitate TEM
[19]. This gap formation is mediated by VCAM-1 [20,21].
VCAM-1 clustering also increases the intracellular free cal-
cium concentration [20]. Thus, VCAM-1 expression in-
creases vascular endothelium permeability and leukocyte
TEM, contributes to vascular damage and ETD, and in-
duces the generation of atherosclerosis.
The endothelial expression of ICAM-1 is increased in
atherosclerosis and in animal models of atherosclerosis
[22,23]. ICAM-1 is normally present in low levels on ECs,
but its expression is dramatically increased in response to
proinflammatory stimuli, including the proinflammatory
cytokines TNF-α, IL-1β, and interferon-γ [23]. Soluble
ICAM-1 may modulate leukocyte adhesion and migration.
Facilitating leukocyte attachment to the endothelial surface
is not the only function of ICAM-1. Engagement of ICAM-
1 also induces signaling in ECs, increases the production of
IL-8 and induces expression of ICAM-1 and c-fos. It is pos-
sible that proinflammatory IL-8 and c-fos activation by
ICAM-1 initiates a positive feedback loop, leading to more
ICAM-1 and VCAM-1 expression and thereby promoting
the sustained recruitment of leukocytes to areas of athero-
sclerosis, accelerating the process of atherosclerosis by
proinflammatory stimuli via indirect or direct ETD [24-26].
P-selectin is also regulated by proinflammatory stimuli,
which is stored in intracellular vesicles of ECs that fuse
with the plasma membrane in response to a number of
stimuli, including ischemia and chronic hyperglycaemia
[27]. In some circumstances, P-selectin translocation to the
EC surface is regulated through a ROS-dependent mech-
anism. P-selectin clustering increases cytosolic free calcium
and induces changes in cell morphology, promoting ETD
to consequently produce vascular damage [28-30].
As described above, the previous research reflected the
expression, regulation and function of the three adhesion
molecules (ICAM-1, VCAM-1 and P-selectin). First, there
is evidence that expression of the soluble adhesion mole-
cules VCAM-1, ICAM-1 and P-selectin is associated with
proinflammatory stimuli. Elevated levels of endothelial ad-
hesion molecules (EAM) may, to some extent, reflect a
chronic inflammatory state, because systemic inflammation
can directly elicit overproduction of EAM [31]. Second, the
atherosclerotic process appears to be associated with alter-
ations in adhesion molecules of endothelial function-
associated vasoactivators because VCAM-1, ICAM-1 andP-selectin play an important role in vascular integrity
and permeability via ETD [32]. Elevated levels of soluble
EAM may be one of the common antecedents for the
pathogenesis of both atherosclerotic CVD and ETD
[32]. The expression of endothelial cellular adhesion
molecules promotes the adherence and transmigration
of leukocytes into the subendothelial space, eventually
leading to ETD and subendothelial structural changes
[33]. Increased vascular permeability due to structural
alterations can then reduce insulin delivery to insulin-
sensitive peripheral tissues, which in turn produces in-
sulin resistance. Alternatively, insulin resistance may
directly promote ETD [34]. The study in nondiabetic in-
dividuals have suggested that mildly impaired glucose
tolerance within the normoglycemic range may acceler-
ate the progression of ETD via adverse effects on oxida-
tive stress, formation of advanced glycation end
products, and elevated levels of free fatty acids [35].
Vascular ETD may precede insulin resistance, induce a
reduction in insulin sensitivity, and produce a malignant
cycle [36-38].
Our results show a significant increase in VCAM-1,
ICAM-1 and P-selectin in CVD susceptible brain regions
of T2DM rats (see Figures 3, 4 and 5). The results also
provide experimental evidence of diabetic angiopathy,
which is generated by ETD through increases in VCAM-
1, ICAM-1 and P-selectin. The results also indicate that
diabetes can elicit the expression of adhesion molecules,
including P-selectin, ICAM-1, and VCAM-1, which in-
directly or directly promote development of ETD to in-
duce CVD.
Our study described alterations of ET-1, CGRP, VCAM-
1, ICAM-1 and P-selectin expression in main CVD sus-
ceptible brain regions of T2DM rats (see Figures 1, 2, 3, 4
and 5). These findings highlight the therapeutic potential
of targeting the vascular endothelium activators for pre-
vention and/or treatment of CVD disease in T2DM. Of
note, there is a growing body of evidence on interventions
aimed at mediating individual risk factors correlated with
ETD, such as ET-1, CGRP, VCAM-1, ICAM-1 and P-
selectin. Our studies also support a link between ETD and
T2MD, implicating a role for ETD in the CVD pathogen-
esis of T2DM. To date, very few studies have directly eval-
uated the alterations of ET-1, CGRP, VCAM-1, ICAM-1
and P-selectin in CVD-susceptible brain regions of a
T2DM model. Here, we report that significant expression
alterations of ET-1, CGRP, VCAM-1, ICAM-1 and P-
selectin occurred in CVD susceptible brain regions in
T2DM rats, including the frontal and temporal cerebral
cortex, basal ganglia and thalamus.
Conclusions
Our results offered the more evidences that ETD plays
an etiological role in the pathogenesis of CVD in T2DM,
Xu et al. Diabetology & Metabolic Syndrome 2013, 5:63 Page 10 of 11
http://www.dmsjournal.com/content/5/1/63and also gives new insights into the potential clinical value
of endothelial function modulation in CVD of T2DM. The
pathogenesis of CVD in T2DM might be associated with
an expression imbalance of ET-1, CGRP, VCAM-1, ICAM-
1 and P-selectin, which promotes ETD through a series of
chemical factors, such as ROS, NO and inflammatory fac-
tors. In addition, it was suggest that emotion, cerebral
splanchno-motor and neuroendocrine center might be in-
volved in the pathogenesis of CVD in T2MD via expres-
sion alterations of ET-1, CGRP, VCAM-1, ICAM-1 and
P-selectin. However, further studies are warranted.
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